ADAyşe Nur DEMİRAL

Ayşe Nur DEMİRAL

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ayşe Nur DEMİRAL has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Primary pulmonary NUT carcinoma: Genomic landscape, diagnostic challenges, molecular pathogenesis, and the evolving role of radiotherapy, targeted therapies, and immunotherapy

    by Mehmet Çağrı Duymaz, Kübra Canaslan, Zeynep Bayramoğlu, Cenk Umay, Tuğba Yavuzşen, Emrullah Rıza Çetingöz, Ayten Kayı Cangır, Fatemeh Ardeshir-Larijani, Ayşe Demiral

  • Open Access

    Pretreatment EBV ‐ DNA / TLG ‐Based Risk Stratification Is Associated With Survival Outcomes in Nonmetastatic Nasopharyngeal Carcinoma: An Exploratory Study

    by Mehmet Çağrı Duymaz, Ece Özkaya Duymaz, Nazlı Ünsal, Recep Bekiş, Büşra Tozduman, Özgür Appak, Ayşe Demiral, Oğuz Çetinayak

    Whether combining pretreatment plasma Epstein–Barr virus DNA (EBV‐DNA) with 18F‐FDG PET/CT‐derived total lesion glycolysis (TLG) improves prognostic stratification in nonmetastatic nasopharyngeal carcinoma (NPC) is unclear, particularly in nonendemic populations. We retrospectively analyzed 86 eligible nonmetastatic NPC patients treated with definitive radiotherapy (2010–2024) at a single nonendemic‐region institution. EBV‐DNA (prespecified cutoff 3500 copies/mL) and TLG (cutoff 200, ROC‐derived within this cohort) were dichotomized. Both were available in 59/86 patients (68.6%), who differed from the rest in nodal and overall stage and in RT technique. Baseline PET/CT was in‐house in 57 of 86 patients, and a robustness analysis in that subgroup is reported. Given limited events (13 PFS, 9 OS), Cox analyses are exploratory and were supplemented with penalized regression and bootstrap validation. At a median follow‐up of 75.5 months, 5‐year PFS and OS for the whole cohort ( n = 86) were 81.1% and 85.9%. The EBV‐DNA high /TLG high subgroup remained associated with inferior PFS after adjustment in an exploratory model (adjusted HR = 3.97, 95% CI: 1.32–11.93) and, in a single‐variable model, with inferior OS (HR = 4.13, 95% CI: 1.10–15.52). Discrimination was comparable to the individual‐biomarker model for PFS and lower for OS. Five‐year PFS fell monotonically across the four risk groups in the complete‐case cohort ( n = 59; 89.7%–58.3%). OS differed across groups (log‐rank p = 0.044) but was not strictly monotonic, with wide, overlapping confidence intervals. This two‐biomarker model is hypothesis‐generating and needs prospective, multicenter validation before any consideration of risk‐adapted treatment.

  • Radiation Therapy Outcomes of the National Protocol in Childhood Neuroblastomas: Turkish Society for Radiation Oncology Hematological Oncology, Pediatric Oncology, and TBI Working Group Study (TROD 03-004)

    by Melis Gultekin, Melek Tugce Yilmaz, Ferah Yildiz, Serra Kamer, Ayse Nur Demiral, Bilge Gursel, Zeynep Gural, Fulya Agaoglu, Sumerya Duru Birgi, Vuslat Yurut Caloglu, et al.

  • Pediatric paravertebral tumors: analysis of 96 patients

    by Deniz Kizmazoglu, Dilek Ince, Emre Cecen, Ceren Kizmazoglu, Handan Guleryuz, Erdener Ozer, Ayse Demiral, Nur Olgun

    Purpose The most important complication of paravertebral tumors is cord compression (CC), which is an oncologic emergency. Early and appropriate intervention is important in terms of reducing morbidity and mortality. Here, we report our clinical experience with paravertebral tumors. Methods The files of patients who were followed up for benign/malignant paravertebral tumors between 1988 and 2022 were evaluated retrospectively. Results There were 96 patients with paravertebral tumors. The median age at diagnosis was 5 years (1 month–17 years). The male/female ratio was 1.13. The median time to diagnosis was 4 weeks (0–28 weeks). The most common presenting complaint was pain (62.5%). The diagnosis distribution was as follows: sympathetic nervous system (SNS) tumors (n: 38), soft tissue sarcomas (STS) (n: 23), Langerhans cell histiocytosis (LCH) (n: 12), central nervous system (CNS) tumors (n: 9), germ cell tumor (n: 6), lymphomas (n: 4), and benign tumors (n: 4). Sixty-five patients (67.7%) had CC, 40% of whom received chemotherapy as first-line treatment. Decompression surgery was performed in 58.5% of the patients. For patients with CC, 26 patients had advanced disease at admission. Serious neurologic sequelae were observed in seventeen (17.7%) patients. Conclusion Pain and neurological findings in childhood are warning signs for paravertebral tumors and CC. A detailed neurologic examination and radiodiagnostic imaging should be performed, and a definitive diagnosis should be made quickly. Anticancer treatment should be planned multidisciplinary. Decompression surgery should be discussed for patients with severe neurological deficits. Childhood cancers are chemosensitive; if possible, treatment should be initiated with chemotherapy to avoid neurological sequelae.


  • Comparison of Hybrid Techniques with 3D-Conformal Radiotherapy in Patients with Lung Cancer

    by Ömer Azaklioğlu, Doğukan AKÇAY, İlhami Er, Kadir Akgüngör, Ayşe Nur DEMİRAL

    Purpose: It’s postulated that hybrid techniques (HT) with lower weighting of IMRT/VMAT component would improve lung dose-volume parameters despite some disadvantage in PTV homogeneity index (HI) and target coverage (TC). Material and Methods: Conformal plans were prepared using 6-10-15 MV-X photon energies while IMRT/VMAT plans of HTs were prepared using 6MV-X. Four HTs were developed having two different ratios (10% and 50%) of IMRT/VMAT component (h-IMRT1, h-IMRT2 and h-VMAT1, h-VMAT2, respectively). HTs were compared with 3D-CRT in terms of HI and TC for PTV, and total lung (TL) and contralateral lung (CL) V5Gy, V10Gy, V20Gy and mean lung dose (MLD). Results: All HTs were advantageous for HI and TC, while disadvantageous for TL and CL-V5Gy. H-IMRT2 provided better TC than h-IMRT1, and so did h-VMAT2 compared to h-VMAT1. Lower weighting of IMRT/VMAT decreased TL and CL-V5Gy in HTs. In addition, h-IMRT1 decreased TL and CL-MLD and CL-V20Gy compared to h-IMRT2, while h-VMAT2 decreased TL-V20Gy and CL-MLD compared to h-VMAT2. Conclusion: In the RT of lung tumors close to vertebra, it may be appropriate to suggest a ratio of IMRT/VMAT component about 10% in order to decrease the low and intermediate dose-wash lung volume, if HI and TC values are acceptable.

  • EVALUATION OF CLINICAL STUDIES USING KNOWLEDGE BASED PLANNING METHODS IN THE RADIOTHERAPY OF PROSTATE CANCER WITH VOLUMETRIC MODULATED ARC THERAPY

    by Şeyda Kinay, Doğukan AKÇAY, Cenk Umay, Barbaros Aydin, Dilara Gülşan, Kadir Akgüngör, Ayşe Nur DEMİRAL

    Bilgi Tabanlı Planlama (“Knowledge Based Planningˮ-KBP), klinik olarak kabul edilebilir Yoğunluk Ayarlı Radyoterapi (“Intensity Modulated Radiotherapy”-IMRT) ve Hacimsel Modülasyonlu Ark Tedavisi (“Volumetric Modulated Arc Therapy”-VMAT) planlarını minimum iş akışıyla optimize etmek için bilgi tabanlı modeller (“Knowledge Based Model”–KBM) kullanarak plan kalitesini standart hale getirmeyi amaçlar. KBP, Risk Altındaki Organlar (‟Organ at Risk”-OAR) için ulaşılabilir Doz-Volüm Histogramı (DVH)’nı tahmin eder ve her bir yeni hasta için ideal optimizasyon hedefleri sağlar. KBP modeli, plan kalitesini iyileştirir, plan tutarlılığını koruyarak planlayıcılar arası değişkenliği azaltır ve simülasyondan tedavi başlangıcına dek geçen süreyi kısaltır. Bu derlemede prostat kanserinin VMAT tekniği ile tedavisinde KBP tabanlı yöntemlerin kullanıldığı klinik çalışmaların sonuçları incelendi. “Knowledge-based treatment planning”, “prostate cancer”, “VMAT” anahtar kelimeleri kullanılarak “PubMed” tarama motorunda “Clinical Trial” kategorisindeki İngilizce olarak yayınlanmış makalelerin taranması sonucu ulaşılan beş adet çalışma derleme kapsamına alındı. Bu klinik çalışmaların tümünde temelde KBP modelinin dozimetrik ve mekanik performansını değerlendirmek ve optimize etmek istenmiştir. Bu nedenle her bir kliniğin deneyimine göre hazırlanan manuel planlar, KBP ile oluşturulan otomatik planlar ile karşılaştırılmıştır. Prostat kanserinin VMAT planlamasında KBP kullanımı, doğrulama çalışmalarında, güçlü bir şekilde performans göstermiştir. KBP yöntemleri, plan kalitesi açısından genellikle uzman seviyesindeki planlayıcılara eşdeğerdir ancak ön sonuçlar, önemli ölçüde daha gelişmiş olduklarını göstermektedir. Hedef volüm ile örtüşen OAR volümlerinin dikkate alındığı KBP modellerinin örtüşme volüm histogramı (“overlap volüme histogram”-OVH) rehberliğinde daha hassas ve doğru doz tahminleri yapabileceği düşünülmektedir. KBP yöntemlerinin uygulaması sırasında dozimetrik ve mekanik performansın yanı sıra hastaya özgü kalite güvenirliğini (“Quality Assurance” –QA) doğrulamak da çok önemlidir.


  • Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study

    by Bilgehan Sahin, Banu Atalar, Esra Kaytan Saglam, Zuleyha Akgun, Ufuk Abacioglu, Alptekin Arifoglu, Enis Ozyar, Gokhan Yaprak, Naciye Ozseker Isik, Yıldız Guney, et al.

    Objective We identified factors influencing outcomes in patients with medically inoperable early‐stage lung cancer (MIESLC) treated with stereotactic ablative radiation therapy (SABR) at 14 centers in Turkey. Methods We retrospectively analyzed 431 patients with stage I‐II MIESLC treated with SABR from 2009 through 2017. Age; sex; performance score; imaging technique; tumor histology and size; disease stage radiation dose, fraction, and biologically effective dose with an α/β ratio of 10 (BED10); tumor location; and treatment center were evaluated for associations with overall survival (OS), local control (LC), and toxicity. Results Median follow‐up time was 27 months (range 1–115); median SABR dose was 54Gy (range 30–70) given in a median 3 fractions (range 1–10); median BED10 was151 Gy (range 48–180). Tumors were peripheral in 285 patients (66.1%), central in 69 (16%), and 100Gy (p =0.011), adenocarcinoma (p =0.025), and complete response on first evaluation (p =0.007) predicted favorable LC. BED10>120Gy (hazard ratio [HR] 1.9, 95% confidence interval [CI] 1.1–3.2,p =0.019) and tumor size (p =0.003) predicted favorable OS. No grade 4‐5 acute side effects were observed; late effects were grade ≤3 pneumonitis (18 [4.2%]), chest wall pain (11 [2.5%]), and rib fracture (1 [0.2%]). Conclusion SABR produced encouraging results, with satisfactory LC and OS and minimal toxicity. BED10>120 Gy was needed for better LC and OS for large, non‐adenocarcinoma tumors.